Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis
Trethera Announces U.S. Patent Application Filed for TRE-515, Extending Major Markets Exclusivity until 2041